Targeted immunotherapy alone probably leads to lower adverse events (grade ≥ 3) compared with standard targeted therapies (moderate certainty).
Early taxane‐based chemotherapy and androgen deprivation therapy (ADT) may leads to higher grade III to V adverse events compared with ADT only (low certainty).
Interferon‐α combined with targeted therapies may leads to higher adverse events (grade ≥ 3) compared with standard targeted therapy (low certainty).
Immune checkpoint inhibitors probably leads to lower adverse events grade 3 to 5 Range of compared with any first‐line chemotherapy (moderate certainty).
Immune checkpoint inhibitors may leads to lower adverse events grade 3 to 5 Range of compared with any second‐line chemotherapy (low certainty).
Sunitinib showed no clear difference in serious adverse events (Grade 3 or 4) compared with avelumab + axitinib (targeted agent versus immunotherapy + targeted… (low certainty).
Sunitinib showed no clear difference in serious adverse events (Grade 3 or 4) compared with pembrolizumab + axitinib (targeted agent versus immunotherapy +… (low certainty).
It is very uncertain whether sunitinib changes serious adverse events (Grade 3 or 4) compared with atezolizumab + bevacizumab (targeted agent versus immunotherapy +… (very low certainty).
Temsirolimus may leads to lower serious adverse events (Grade 3 or 4) compared with IFN‐α (targeted agent versus classic immunotherapy) (low certainty).
Sunitinib probably leads to higher serious adverse events (Grade 3 or 4) compared with atezolizumab (targeted therapy versus immunotherapy) (moderate certainty).
Bevacizumab + IFN probably leads to higher serious adverse events (Grade 3 or 4) compared with IFN (+ placebo) (targeted agent + classic immunotherapy versus… (moderate certainty).
Temsirolimus + IFN‐α may leads to higher serious adverse events (Grade 3 or 4) compared with IFN‐α (targeted agent + classic immunotherapy versus classic… (low certainty).
Temsirolimus + bevacizumab showed no clear difference in serious adverse events (Grade 3 or 4) compared with bevacizumab + IFN‐α (targeted agent + targeted agent versus targeted… (low certainty).
Everolimus + bevacizumab showed no clear difference in serious adverse events (Grade 3 or 4) compared with IFN α‐2a + bevacizumab (targeted agent + targeted agent versus… (low certainty).
Sunitinib probably leads to higher serious adverse events (Grade 3 or 4) compared with nivolumab + ipilimumab (targeted agent versus combinations of… (moderate certainty).
Sunitinib probably leads to higher serious adverse events (Grade 3 or 4)assessed as: CTCAE v3.0 compared with interferon‐α (IFN‐α) (targeted agent versus classic immunotherapy) (moderate certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Interferon‐α alone probably leads to lower adverse events (grade ≥ 3) compared with interferon‐α plus bevacizumab (moderate certainty).
Interferon‐α plus bevacizumab showed no clear difference in adverse events (grade ≥ 3) compared with standard targeted therapies (low certainty).